Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Cochrane Database Syst Rev
05 June 2018
https://www.ncbi.nlm.nih.gov/pubmed/29869799

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion

Cureus
10 July 2018
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126779/

Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin

Exp Biol Med (Maywood)
July 2011
https://pubmed.ncbi.nlm.nih.gov/21685240/

Low-dose naltrexone: A possible safe effective treatment for autoimmune disease and cancer

Anti-Aging Therapeutics, Volume 12, Chapter 3
January 2009
https://books.google.co.il/books?id=BSfzEE0tT9cC&lpg=PR7&dq=low%20dose%20naltrexone&pg=PR7#v=onepage&q=low%20dose%20naltrexone&f=false

The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma

PLoS One
04 October 2018
https://pubmed.ncbi.nlm.nih.gov/30286124/

Low Dose Naltrexone in Dermatology

J Drugs Dermatol
March 2019
https://jddonline.com/articles/dermatology/S1545961619P0235X

Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy

Int Immunopharmacol
09 August 2019
https://pubmed.ncbi.nlm.nih.gov/31404891/

Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer

Curr Drug Res Rev
26 Jan 2021
https://pubmed.ncbi.nlm.nih.gov/33504322/

The LDN Book Volume 2 & The Goals of the LDN Research Trust (LDN, low-dose Naltrexone) from LDN Research Trust on Vimeo.

LDN Radio Show Dr Neil Paulvin, Dec 2020 (Low dose naltrexone) from LDN Research Trust on Vimeo.